NCT03558997 - Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

May 14, 2019

Study Completion Date

June 13, 2019

Conditions

Allergic Rhinitis

Interventions

DRUG

Dupilumab

Dupilumab was administered SC in a single-use, pre-filled glass syringe

DRUG

Timothy Grass SCIT

Timothy grass extract was administered SC.

DRUG

Placebo matching dupilumab

Placebo matching dupilumab was prepared in the same formulation without the addition of protein

DRUG

Placebo matching SCIT

Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract

Trial Locations (17)

21224

Regeneron Investigational Site, Baltimore

63141

Regeneron Investigational Site, St Louis

68123

Regeneron Investigational Site, Bellevue

90025

Regeneron Investigational Site, Los Angeles

94040

Regeneron Investigational Site, Mountain View

94598

Regeneron Investigational Site, Walnut Creek

97202

Regeneron Investigational Site, Portland

98115

Regeneron Investigational Site, Seattle

01810

Regeneron Investigational Site, Andover

02747

Regeneron Investigational Site, North Dartmouth

02914

Regeneron Investigational Site, East Providence

53792-9988

Regeneron Investigational Site, Madison

K7L 2V7

Regeneron Investigational Site, Kingston

L5A 3V4

Regeneron Investigational Site, Mississauga

K1G 6C6

Regeneron Investigational Site, Ottawa

M4V 1R2

Regeneron Investigational Site, Toronto

G1V 4W2

Regeneron Investigational Site, Québec